Chromogranin A (CgA) in the Diagnosis and Monitoring of Patients with Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NET): A Single-Institution Experience

被引：0
|
作者：
Massironi, S. [1 ]
Rossi, R. E.
Spampatti, M. P.
Casazza, G. [2 ]
Conte, D.
Ciafardini, C.
Cavalcoli, F.
Peracchi, M.
机构：
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[2] Univ Milan, Dept Clin Sci L Sacco, Milan, Italy
来源：
NEUROENDOCRINOLOGY | 2012年 / 96卷
关键词：
cga; gep-net;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：48 / 48
页数：1
相关论文
共 21 条
  • [1] Evaluation of Early Predictors of Metabolic Syndrome in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
    Modica, R.
    Barrea, L.
    Bottiglieri, F.
    de Cicco, F.
    Minotta, R.
    Muscogiuri, G.
    Savastano, S.
    Faggiano, A.
    Colao, A.
    NEUROENDOCRINOLOGY, 2020, 110 : 95 - 95
  • [2] Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors
    Singh, Simron
    Law, Calvin
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 6 (03) : 313 - 334
  • [3] Thrombotic Risk in Gastroenteropancreatic Neuroendocrine Tumors: A Single Centre Experience
    Cavalcoli, F. A.
    Rossi, R. E.
    Artoni, A.
    Sciola, V
    Zilli, A.
    Ciafardini, C.
    Massironi, S.
    NEUROENDOCRINOLOGY, 2018, 106 : 65 - 65
  • [4] Theragnostic Approach of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) - The Role of Nuclear Medicine (NM) in a Multidisciplinary Team
    Lucio, T.
    Gaspar, C.
    Cunha, C.
    Roque, R.
    Gloria, L.
    Costa, J.
    Strecht, J.
    Oliveira, H.
    Madureira, R.
    Teixeira, J.
    Rodrigues, T.
    Catarino, A.
    Vieira, R.
    NEUROENDOCRINOLOGY, 2016, 103 : 93 - 94
  • [5] The Role of Plasma Chromogranin A as Assessment of Treatment Response in Grade 1-3 Non-Functioning Gastroenteropancreatic (GEP) Neuroendocrine Tumors
    Park, Y.
    Kim, S.
    Lee, J.
    Park, S.
    Park, J.
    Kang, W.
    Im, H.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 268 - 269
  • [6] Prognosis of Stage IV Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) According to the WHO Classification and the Primary Tumor Location
    Carmona-Bayonas, A.
    Jimenez-Fonseca, P.
    Vieitez, J. M.
    Menendez Prieto, M. D.
    Soli, M. P.
    Sanchez, M. L.
    Rodriguez, D.
    Ruiz, A. L.
    Faez, L.
    Li, W.
    Uriol, E.
    Crespo, G.
    Castano, A.
    Garcia-Carbonero, R.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 93 - 93
  • [7] Somatostatin analogues (SSA) in gastroenteropancreatic neuroendocrine tumors (GEP-NET) - Impact on glycemia and lipid profile in a monocentric series
    Cannavale, G.
    Benevento, E.
    Minotta, R.
    Liccardi, A.
    Modica, R.
    Colao, A.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 68 - 68
  • [8] Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in Precision-Medicine Era
    Kim, S.
    Yoo, K.
    Jung, K.
    Lee, S.
    Lee, J.
    Park, S.
    Park, J.
    Lim, H.
    Kang, W.
    Park, Y.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 85 - 86
  • [9] Is True Non-Secretion of Chromogranin A an Unfavorable Prognostic Factor in Patients with ENETs TNM Stage IV Gastroenteropancreatic Neuroendocrine Tumors?
    Kamp, K.
    Adrichem, van R. C. S.
    Vandamme, T.
    Peeters, M.
    Feelders, R.
    De Herder, W.
    NEUROENDOCRINOLOGY, 2016, 103 : 47 - 47
  • [10] Trends in Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in India: A Report of Multicentre Data from a Web Based Registry
    Desai, G.
    Pande, P.
    Mansukhani, V
    Shah, R.
    Bhaduri, D.
    Sirohi, B.
    Shrikhande, S.
    Dhar, P.
    Sastry, R.
    Sikora, S.
    Palepu, J.
    NEUROENDOCRINOLOGY, 2018, 106 : 70 - 70
123